Raxatrigine-GSK-1014802-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemERaxatrigineCat. No.: HY-12796CAS No.: 934240-30-9Synonyms: GSK-1014802; CNV1014802分式: CHFNO分量: 314.35作靶点: Sodium Channel作通路: Membrane Transporter/Ion Channel储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶

2、解性数据体外实验 DMSO : 83 mg/mL (264.04 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 3.1812 mL 15.9058 mL 31.8117 mL5 mM 0.6362 mL 3.1812 mL 6.3623 mL10 mM 0.3181 mL 1.5906 mL 3.1812 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Raxatrigine (GSK-

3、1014802)钠离通道Nav1.7有效抑制剂。IC50 & Target Sodium channel blocker 1.体外研究Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced byPCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However,1/2 Master of Small Molecules

4、 您边的抑制剂师www.MedChemEhigher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in thereversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent centralside effects for this indication. Raxatrigine (GSK-1014802) received orph

5、an-drug designation from the USFood and Drug Administration in July 2013.REFERENCES1. Large CH, et al. The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: potential fornovel treatments for schizophrenia. J Pharmacol Exp Ther. 2011 Jul;338(1):100-13.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021